Bausch HealthBHC +2.73%58 Receivables Turnover is 1.11 as of Mar. 2026. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.85 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 943 Drug Manufacturers companies, Bausch Health ranks worse than 55.46% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Bausch Health's Revenue for the
three
months ended in Mar. 2026 was $2,524 Mil. Bausch Health's average Accounts Receivable for the
three
months ended in Mar. 2026 was $2,271 Mil.
Hence, Bausch Health's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.11.
Bausch Health (NYSE:BHC) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Bausch Health Receivables Turnover Related Terms
Bausch Health Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Bausch Health's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Bausch Health's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (BHC) has a Receivables Turnover of 1.11 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bausch Health and its competitors. According to the industry distribution chart, Bausch Health ranks #523 out of 943 companies in the Drug Manufacturers industry, placing it in the top 55.5%.
Is Bausch Health's Receivables Turnover too high?
Bausch Health's current Receivables Turnover is 1.11. The Drug Manufacturers industry median Receivables Turnover is 5.07. Bausch Health's value of 1.11 is 78.1% below this industry median. Based on the distribution chart, Bausch Health ranks #523 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #523 out of 943 companies for Receivables Turnover. This places Bausch Health in the lower half of its industry. The industry median Receivables Turnover is 5.07. Bausch Health's value of 1.11 is 78.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch Health's current Receivables Turnover of 1.11 is 78.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current Receivables Turnover is 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Possible Value Trap. The stock's GF Value™ is $7.85, compared to a current price of $4.90 — trading 37.6% below its estimated fair value. The current Receivables Turnover is 1.11 and 78.1% below the Drug Manufacturers industry median of 5.07. Bausch Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Bausch Health (BHC), the current Receivables Turnover is 1.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (BHC) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of $4.90 is trading 37.6% below its estimated GF Value™ of $7.85.
GuruFocus considers Bausch Health to be Possible Value Trap.
Key valuation signals for BHC:
Receivables Turnover: 1.11
GF Value™: $7.85 vs. price of $4.90 (37.6% below fair value)
Industry Position: 78.1% below the Drug Manufacturers median (#523 of 943)
No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score
Get the complete analysis for BHC
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHC has been successfully added to your 
